ClinicalTrials.gg
RecruitingNCT07244510Updated Apr 28, 2026

Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 2 interventional study of SCT650C in Hidradenitis Suppurativa (HS), sponsored by Sinocelltech Ltd.. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Sinocelltech Ltd. (part of Sinocelltech Group Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Hidradenitis Suppurativa with a site in Turkey — 2 open to participants now, 5 under way, 3 of them phase 3. Hidradenitis Suppurativa · Turkey.

Planned enrollment
13th of 13
60 · median 544
Started
2025
with 4 others
Phase 2
3 of 16
2 open now
Registered
14th of 16
by date
Lead sponsor
1 of 16
Sinocelltech Ltd.

Among the 16 studies in Hidradenitis Suppurativa with a site in Turkey, this one is the 13th largest by planned enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2025, is one of 3 in phase 2, and was the 14th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

2 of the 16 studies in Hidradenitis Suppurativa with a site in Turkey are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Hidradenitis Suppurativa with a site in Turkey, or all of them as a file.
02

Study summary

The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SCT650C in patients with Moderate to Severe Hidradenitis Suppurativa

Read the detailed description

This is a Phase II, multicenter, double-blinded, placebo-controlled study to evaluate the safety and efficacy of SCT650C in adult participants with Moderate to Severe Hidradenitis Suppurativa. This study includes 3 periods (Screening period, Loading period and Maintenance period ), and ≤ 60 participants in 3 groups (Group 1, 2 and 3)

03

Conditions studied

  • Hidradenitis Suppurativa (HS)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participants must be at least 18 years of age at the time of signing the ICF.
  2. Study participants must have a diagnosis of HS based on clinical history and physical examination for at least 6 months prior to the baseline visit; diagnosis must be verifiable through medical notes and documentation.
  3. Study participants must have HS lesions in at least 2 distinct anatomic areas (eg, left and right axilla), 1 of which must be at least Hurley Stage II or Hurley Stage III at both the Screening and Baseline visits.
  4. Study participants must have moderate to severe HS defined as a total of ≥ 5 inflammatory lesions (ie, number of abscesses plus number of inflammatory nodules) at both the Screening and Baseline visits.
  5. Study participants must have had a history of inadequate response, intolerance or to a course of systemic antibiotics for treatment of HS at the Screening Visit as assessed by the investigator.
  6. Participants agree to daily use of topical antiseptics on the areas affected by HS lesions while on study treatment. Allowable antiseptic washes are limited to one of the following: chlorhexidine gluconate, benzoyl peroxide, benzalkonium chloride, benzethonium chloride, or dilute bleach in bath water.
  7. Participants entering the study while undergoing concomitant treatment with systemic antibiotics (as specified in the protocol) must be on a stable dose. A stable dose is defined as a dosage or regimen that has remained unchanged for at least four weeks prior to baseline and is expected to remain unchanged for at least the first 16 weeks of the study.
  8. Female participants must be not of or permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy) or, if of childbearing potential (and engaged in sexual activity that could result in procreation), must be willing to use a highly effective method of up to 40 weeks after the last administration of the medical product (IMP) and have a negative pregnancy test prior to the first dose. The following methods are considered highly effective when used consistently and correctly:

    1. progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable);
    2. combined (estrogen and progestogen) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal);
    3. intrauterine device (IUD);
    4. intrauterine hormone-releasing system (IUS);
    5. bilateral tubal occlusion;
    6. vasectomized partner (where postvasectomy testing had demonstrated sperm clearance);
    7. Sexual abstinence if it is in accordance with a participant's preferred and common lifestyle.

    Note: Participants who use abstinence as a form of birth control must agree to abstain from heterosexual intercourse until 40 weeks after the final dose of IMP. Study personnel must confirm the continued use of abstinence is still in accordance with the participant's lifestyle at regular intervals during the study.

    Male participants with a partner of childbearing potential must be willing to use a condom when sexually active, until 40 weeks after the last administration of IMP.

  9. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written form is signed and dated by the participant.

Exclusion criteria

Exclusion Criteria:

  1. Study participant has any medical or psychiatric condition could jeopardize or would compromise the study participant's ability to participate in this study as determined by the investigator based on protocol-required assessments.
  2. Study participant has a draining fistula count of > 20 at the Baseline Visit.
  3. Study participant has any other active skin disease or condition (eg, bacterial cellulitis, candida intertrigo, extensive condyloma) that may, in the opinion of the investigator, interfere with the assessment of HS.
  4. Study participant has a diagnosis of sarcoidosis, systemic lupus erythematosus, or active inflammatory bowel disease (IBD).
  5. Study participant has a primary condition, including taking immunosuppressive therapy following an organ transplant or has had a splenectomy.
  6. Female study participant who is breastfeeding, pregnant, or plans to become pregnant during the study or within 40 weeks following the final dose of IMP.
  7. Study participant has an active infection or history of infection(s) as follows:

    • Any infection requiring systemic treatment within 28 days prior to Baseline;
    • A history of opportunistic, recurrent, or chronic infections that, in the opinion of the investigator, might cause this study to be detrimental to the study participant.

    Opportunistic infections are infections caused by uncommon pathogens (eg, Pneumocystis jirovicii, cryptococcosis), or unusually severe infections caused by common pathogens (eg, cytomegalovirus, herpes zoster).

  8. Study participant has any of the following (for more information, refer to Section 9.2):

    • Known active tuberculosis (TB) disease;
    • History of active TB involving any organ system unless adequately treated according to World Health Organization/ Centers for Disease Control and Prevention therapeutic guidance and proven to be fully recovered upon consult with a TB specialist.
    • Latent TB infection (LTBI).
    • High risk of acquiring TB infection.
    • Current or history of NTMB infection.
  9. Study participant has an acute or chronic virus, virus (HCV), or (HIV) infection or treponema pallidum antibody (TPPA) positive. Study participants who have evidence of, or tested positive for, hepatitis B or hepatitis C will be excluded.

    1. A positive test for hepatitis B virus is defined as: 1) positive for hepatitis B surface antigen (HBsAg+), or 2) HBsAg is negative, HBcAb is positive and HBV-DNA test results ≥ the upper limit of the reference value of each center or need antiviral treatment.
    2. A positive test for HCV is defined as: 1) positive for hepatitis C antibody (HCVAb+); and 2) positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction).
  10. Study participants with concurrent are excluded. Study participants with a history of malignancy within the past 5 years prior to the Screening Visit are excluded, EXCEPT if the malignancy was a cutaneous squamous or basal cell carcinoma, or in situ cervical cancer that has been treated and is considered cured.
  11. Study participant has a history of a lymphoproliferative disorder including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease.
  12. Study participant has had major surgery within the 3 months prior to the Baseline Visit, or has planned major surgery after entering the study.
  13. Study participant has any systemic disease (ie, cardiovascular, neurological, renal, liver, metabolic, gastrointestinal, hematological, immunological, etc.) considered by the investigator to be uncontrolled, unstable, or likely to progress to a degree during the course of the study.
  14. Study participant has had a myocardial infarction or stroke within the 6 months prior to the Screening Visit.
  15. Study participant has a history of chronic alcohol or drug abuse within 6 months prior to Screening as evaluated by the investigator based on medical history and interview.
  16. Study participant has a history of depression and/or suicidal thoughts or behaviors are considered not suitable for participation in the clinical study by the investigator.
  17. The participant has a known to any of SCT650C.
  18. Study participants with prior exposure to biologic agents that block IL-12/23 (e.g., ustekinumab), IL-23 (e.g., risankizumab, guselkumab), or IL-17 (e.g., secukinumab) within 3 months prior to the Baseline visit.
  19. Study participants with prior exposure to anti-TNF therapy (e.g., adalimumab, infliximab) for any indication within 2 months prior to the Baseline visit.
  20. Study participants who have had prior exposure to other immunomodulatory biologic therapies, including anti-IL-1 (e.g., anakinra, canakinumab), within 3 months or 5 half-lives, whichever is longer, prior to the Baseline visit.
  21. Previous treatment with any cell-depleting therapies, including but not limited to anti-CD20 (e.g., rituximab) within 12 months prior to the Baseline visit or until B cell count returns to normal level.
  22. Use of traditional medicines or herbal remedies within 28 days prior to the Baseline visit.
  23. Study participants have received non-allowable topical therapies (including topical antibiotics) for the treatment of HS within 14 days prior to the Baseline visit.
  24. Study participants have received systemic non-biologic therapies (e.g. methotrexate (MTX), cyclosporine A, retinoids, apremilast, phototherapy) for the treatment of HS within 28 days prior to the Baseline visit.
  25. For HS and non-HS related pain, participants have received oral concomitant analgesics (including opioids) within 14 days prior to the Baseline visit.

    Exception: Participants may continue on non-opioid analgesics provided that the dose and dosing regimen have been stable for at least 14 days preceding the Baseline visit and are expected to remain stable at least until Week 16 visit.

  26. Study participants have received any within 8 weeks prior to the first dose of study drug (Baseline), or expect the need for live vaccination during study participation including within 40 weeks after the last dose of study drug administration.
  27. Study participants have been treated with any other drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another clinical study.
  28. Study participant has laboratory abnormalities at Screening, including any of the following:

    • >2× the (ULN) of any of the following: (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP)
    • Total >2×ULN
    • White blood cell count \<3.00×103/μL
    • \<1.5×103/μL
    • Lymphocyte count \<500 cells/μL
    • \<8.5g/dL
    • Creatinine >1.5 ×ULN Note: Tests that result in ALT, AST, ALP or total bilirubin up to 25% above the exclusion limit may be repeated for confirmation during the Screening Period. Upon retesting, participants whose ALT, AST, or ALP remain over the above-defined thresholds should not be randomized.
  29. Study participant has an estimated (GFR) as measured by Chronic Kidney Disease Epidemiology Collaboration \<60mL/min/1.73m2 [GFR (male)=(140-age)ⅹWeight/serum creatinineⅹ1.23; GFR (female)=(140-age)ⅹWeight/serum creatinineⅹ1.04].
  30. Study participant has any other laboratory abnormality that, in the investigator's opinion, will prevent the study participant from completing the study or will interfere with the interpretation of the study results.
  31. The participant is a SinoCellTech (SCT) employee or is an employee of third-party organizations involved in the study.
  32. The participant and/or his or her immediate family member is an employee, volunteer, or other worker at the investigative site, either affiliated or not affiliated with this study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    SCT650C high dose Group /Group 1

    SCT650C high dose s.c. multiple doses at specified intervals

    Drug: SCT650C

  • Active comparator
    SCT650C low dose Group /Group 2

    SCT650C low dose s.c., multiple doses at specified intervals

    Drug: SCT650C

  • Placebo comparator
    Placebo Group /Group 3

    Placebo / SCT650C high or low dose s.c., multiple doses at specified intervals

    Drug: SCT650C

Interventions

  • Administered SC

    Also known as: Recombinant anti-IL-17A antibody

06

What researchers measure

Primary outcomes

  1. The percentage of participants achieving HiSCR75 (a 75% reduction from baseline of Hidradenitis Suppurativa Clinical Response [HiSCR]) at Week 16

    HiSCR75 is defined as at least a 75 percent (%) reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining fistula count.

    Time frame: Week 16

Secondary outcomes

  1. The percentage of participants achieving HiSCR50, HiSCR90, and HiSCR100 at specified time points

    HiSCR50 is defined as at least a 50% reduction from Baseline in the total AN count, with no increase from Baseline in abscess or draining fistulas count. HiSCR90 is defined as at least a 90% reduction from Baseline in the total AN count, with no increase from Baseline in abscess or draining fistulas count. HiSCR100 is defined as at least a 100% reduction from Baseline in the total AN count, with no increase from Baseline in abscess or draining fistulas count.

    Time frame: Week 48

  2. The percentage of participants achieving HiSCR75 at specified time points

    HiSCR70 is defined as at least a 75% reduction from Baseline in the total AN count, with no increase from Baseline in abscess or draining fistulas count.

    Time frame: Week 48

  3. The percentage of participants who experience ≥ 1 disease flare at specified time points

    Flare is defined as a greater than or equal to (\>=) 25% increase in AN count with an absolute increase in AN count of \>= 2 relative to Baseline.

    Time frame: Week 48

  4. The change from baseline in the HS-Physician's Global Assessment (HSPGA) at specified time points

    The HSPGA is a validated 6-point scale that is used to measure improvement in inflammatory nodules, abscesses, and draining fistulas. This assessment \[clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5)\] is derived based on totals across all affected body regions.

    Time frame: Week 48

  5. The change from baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) at specified time points

    The IHS4 is a validated tool to dynamically assess HS severity to be used both in real-life and the clinical trials setting. This IHS4 score is calculated as follows: (number of inflammatory nodules multiplied by 1) + (number of abscesses multiplied by 2) + (number of draining fistulae multiplied by 4). A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS.

    Time frame: Week 48

  6. The proportion of participants achieving 30% or more reduction in PGA of Skin Pain Numeric Rating Scale (NRS30) at worst among participants with baseline NRS ≥ 3 at specified time points

    The PGA of Skin Pain-NRS in the past 24 hours will be used to assess pain "at its worst" due to HS in the last 24 hours. The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The PGA of Skin Pain-NRS will be completed by the participant using the Diary. NRS30 is defined as at least 30% reduction and at least 1 unit reduction from baseline in Patient's Global Assessment of Skin Pain.

    Time frame: Week 48

  7. The change from baseline in Dermatology Life Quality Index (DLQI) Total Score at specified time points

    The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult participants with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is selfadministered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL, impairment.

    Time frame: Week 48

  8. Treatment-emergent adverse events (TEAEs), treatment related adverse events (TRAEs), serious adverse events (SAEs) and other safety indicators

    A SAE is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Important medical events. TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment.

    Time frame: Week 48

  9. The drug concentrations of SCT650C at different time points in serum

    Time frame: Week 48

  10. Anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs)

    Time frame: Week 48

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Mar 2027, 14 months after the start.

Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 14 months is close to that.

Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 24, 2025
StartActual
Dec 16, 2025
Primary completionEst.
Mar 12, 2027
CompletionEst.
Feb 16, 2028
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07244510
Lead sponsor
Sinocelltech Ltd.
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Dec 16, 2025
Primary completion
Mar 12, 2027 (estimated)
Completion
Feb 16, 2028 (estimated)
Last update
Apr 28, 2026

Study contacts

Miaomiao Zhang, PhD
Contact
miaomiao_zhang@sinocelltech.com
17628293460
Müge Güler Özden, MD
Contact
mgulerozden@hotmail.com
905324068600

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SCT650C

Start the discussion